Get the latest tech news
DEA Accepts Health Agency's Recommendation to Reclassify Cannabis
Determination must be reviewed by the White House Office of Management and Budget
The DEA’s decision, which the Associated Press is reporting today, to move cannabis from Schedule I to Schedule III of the US Controlled Substances Act comes eight months after the US Department of Health and Human Services initially advocated for the change, finding, “The vast majority of individuals who use marijuana are doing so in a manner that does not lead to dangerous outcomes to themselves or others.” The Biden Administration initiated federal agencies to review the issue in October 2022 – marking the the first time a President has ever made such a request. Commenting on the forthcoming decision, NORML Deputy Director Paul Armentano said, “It is significant for these federal agencies, and the DEA and FDA in particular, to acknowledge publicly for the first time what many patients and advocates have known for decades: that cannabis is a safe and effective therapeutic agent for tens of millions of Americans.” The DEA’s decision notwithstanding, Armentano speculated that federal agencies may ultimately request Congress to create new regulatory pathways for cannabis products, particularly for those marketed for adult use.
Or read this on Hacker News
